lyophilized pharmaceutical preparation of cytotoxic dipeptides, method for preparing the same and us

专利摘要:
LYOPHILIZED PREPARATION OF CYTOToxic DIPEPTIDS The present invention is directed to new lyophilized pharmaceutical preparations comprising a cytotoxic dipeptide such as melphalan flufenamide and one or more excipients (s) selected from the group comprising a polysorbate; a polyethylene glycol; (Beta) -cyclodextrin; (Alpha) - cyclodextrin; hydroxypopyl- (Beta) -cyclodextrin; sulfobutyl- (Beta) -cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; Cremofor EL; Dimethyl sulfoxide; D-mannitol; Trealose; Sucrose and an amino acid. This preparation can still be formulated and is useful in cancer therapy.
公开号:BR112013027584B1
申请号:R112013027584-7
申请日:2012-04-25
公开日:2020-11-03
发明作者:Jack Spira；Frederik Lehmann
申请人:Oncopeptides Ab；
IPC主号:

专利说明:

Technical Field
[001] The present invention is directed to pharmaceutical preparations comprising cytotoxic dipeptides or pharmaceutically acceptable salts thereof, methods for their preparation, compositions comprising lyophilized pharmaceutical preparations and their uses in the treatment of cancer. State of the art
[002] Cancer is a disease that is difficult to cure and that can be fatal. Consequently, efforts to develop new therapies for cancer are constantly in existence in the research society. The vast majority of cancers are present as solid tumors, for example, lung cancer, breast cancer, prostate cancer, while the rest are hematological and lymphoid malignancies, for example, leukemias and lymphomas.
[003] Chemotherapy is always used in an attempt to cure or mitigate the disease. Because cancer cells typically divide rapidly, chemotherapy usually works by rapidly killing the dividing cells. In the broad sense, most chemotherapy drugs work to prevent mitosis (ie, cell division), effectively targeting rapidly dividing cells. Because these drugs cause damage to cells, they are called cytotoxic. Some drugs cause cells to undergo apoptosis (so-called "programmed cell death"). The combination of chemotherapy is always used when two or more drugs having different modes of action are used together in order to optimize the anti-tumor effect, to minimize side effects, and to prevent the development of resistance. The results obtained with chemotherapy vary according to the type of tumor. Some tumors are very sensitive and treatment is therefore highly likely to lead to a cure.
[004] Chemotherapy drugs can generally be divided into alkylating agents, antimetabolites, anthracyclines, plant alkaloids, to-poisomerase inhibitors, and other antitumor agents. The drugs affect cell division or DNA synthesis.
[005] Alkylating agents, such as drugs derived from nitrogen mustard, which is derived from bis (2-chloroethyl) amine, are used as chemotherapeutic drugs in the treatment of a wide variety of neoplastic diseases. Alkylating agents have the ability to covalently link alkyl groups to electron sites in cells. So, these agents act by preventing cell function by forming covalent bonds with hetero atoms in biologically important molecules like RNA, DNA and proteins. Examples of alkylating agents are me-chloretamine, cyclophosphamide, chlorambucil, ifosfamide, temozolomide and mefalan that chemically modify a cell's DNA.
WO01 / 96367 discloses alkylating di- and tripeptides and one or two additional amino acids or amino acid derivatives. These derivatives have been shown to have an improved efficacy in a variety of tumor types.
[007] Melfalan, that is, p- [bis- (2-chloroethyl) amino] phenylalanine, is a mustard nitrogen conjugate and the amino acid phenylalanine, which was synthesized in the mid-1950s (U.S. Patent No. 3,032. 584). This classic alkylating substance has quickly become a valuable drug in the chemotherapeutic field and is still of importance in the treatment of, for example, myeloma. Clinical use of melphalan in the treatment of late stages of solid tumors has, however, been of limited effectiveness. In the search for a more selective action on malignant cells, mel-phalan analogues have thus been synthesized.
[008] Larionov L. F., Cancer Res (1961), 21, 99-104 discloses various derivatives related to melphalan.
[009] STN registration files RN: 1060633-95-5, RN: 88 7609-28-1, RN 790650-89-4, RN: 781606-39-1, RN: 773046-98-3, RN: 767621 -58-9, RN: 760165- 58-0 and RN: 757941-61-0 reveal several derivatives related to melphalan.
[0010] Koltun, M et al., Biopharmaceutics & Drug disposition (210), 31, 450-454 discloses forms of melphalan.
[0011] Ma D Q et al., International Journal of Pharmaceutics (1999), 189, 227-234 discloses forms of melphalan.
[0012] Murav’ev I et al., Farmatsiya (1978), 27, (2), 13-15 (with abstract in Chemical Abstracts no. 1978: 412066) reveals melphalan derivatives.
[0013] Freeze-drying or freezing dehydration is a method for dehydrating samples used to preserve or increase stability or stop degradation. Due to the low water content of lyophilized products, typically around 1-4%, the action of microorganisms and enzymes is inhibited and the life of the product is thus increased. In lyophilization, the sample to be lyophilized is dissolved in an aqueous solution and subsequently frozen after which the surrounding pressure is reduced. The sample is then subjected to sublimation, optionally by the application of heat in order to sublimate the frozen water directly from the solid phase to the gas phase. The final water content in the product is very low, typically around 1% to 4%. Lyophilization is commonly used in the pharmaceutical field in order to increase the half-life of pharmaceutical products. Summary of the Invention
[0014] In general, lipophilic dipeptide ester derivatives suffer from poor solubility in aqueous solutions. Thus, the use of organic solvents, such as DMA (dimethylacetamide), is necessary in order to dissolve such dipeptides. However, organic solvents are often toxic and can also cause destruction of devices and methods used to administer dipeptides to patients, such as cancer patients. Consequently, to overcome the problems with dissolution and provide cytotoxic dipeptides in an organic solvent, there is a need for alternative pharmaceutical preparations of cytotoxic dipeptides having sufficient solubility in physiologically acceptable solutions.
[0015] The present invention relates to lyophilized preparations comprising melphalanyl-Lp-fluorophenylalanine ethyl ester, also known as melfala-na flufenamide, as well as pharmaceutically acceptable salt thereof, in particular, melphalanyl-ethyl ester hydrochloride Lp-fluorophenylalanine, also known as melphalan hydrochloride, fluphenamide or J1.
[0016] One aspect of the present invention is directed to a lyophilized pharmaceutical preparation comprising (i) melphalan flufenamide, or a pharmaceutically acceptable salt; and (ii) at least one excipient selected from the group comprising a polysorbate; a polyethylene glycol; β-cyclodextrin, α-cyclodextrin, hydroxypropyl-β-cyclodextrin; sulfobutyl-ter-β-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose and an amino acid.
[0017] Still an aspect of the present invention is a lyophilized pharmaceutical preparation that is soluble in an aqueous solution.
[0018] Still an aspect of the present invention is a method for the preparation of a lyophilized pharmaceutical preparation as described herein, where: a. flufenamide melphalan, or a pharmaceutically acceptable salt thereof, is dissolved in an organic solvent to obtain a solution of flufen-wet melphalan; B. water is added to the melphalan flufenamide solution to obtain an aqueous melphalan flufenamoda solution, at a concentration of about 0.2-3.0 mg / mL; ç. at least one excipient selected from the group comprising a polysorbate; a polyethylene glycol; β-cyclodextrin; α-cyclodextrin, hydroxypropyl-β-cyclodextrin; sulfobutildter-β-cyclodextrin; lactose; benzyl alcohol; disodium succinate; propylene glycol; Cremofor EL; dimethylsulfoxide, D-mannitol; trehalose; sucrose and an amino acid are added to the fluphenamide melphalan solution; and d. the aqueous solution of melphalan flufenamide containing excipient (s) is subject to lyophilization.
[0019] Still an aspect of the invention is a kit of parts, comprising a first container comprising a lyophilized pharmaceutical preparation as defined herein, and a second container comprising a physiologically acceptable solution.
[0020] Still an aspect of the invention is a lyophilized pharmaceutical preparation as described herein, for use as a medicament.
[0021] Still an aspect of the invention is a kit of parts as described herein, for use as a medicament.
[0022] One aspect of the invention is a lyophilized pharmaceutical preparation as described herein, for use in the treatment and / or prevention of cancer, such as ovarian cancer, lung cancer, bladder cancer, mesothelioma, multiple myeloma, cancer of breast and / or any solid or hematological cancer.
[0023] Still an aspect of the invention is a kit of parts as described herein, for use in the treatment and / or prevention of cancer, such as ovarian cancer, lung cancer, bladder cancer, mesothelioma, multiple myeloma, cancer and / or any solid or hematological cancer.
[0024] Still an aspect of the present invention is a method for the treatment and / or prevention of cancer, such as ovarian cancer, lung cancer, bladder cancer, mesothelioma, multiple myeloma, breast cancer and / or any solid or hematological cancer, thus a lyophilized pharmaceutical preparation as described herein, is administered in a therapeutically effective dose to a patient in need thereof.
[0025] Unless otherwise defined, all technical and scientific terms used here have the same meaning as commonly understood by one skilled in the art to which the invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned here are incorporated by reference in their entirety. In the event of a conflict, this specification, including definitions, will replace. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.
[0026] Other features and advantages of the invention will be apparent from the following detailed description, drawings, examples and from the claims. Brief description of the drawings Figs. 1A-D contain graphs of four repeated dissolution rate measurements of lyophilized flufenamide melphalan without excipients by method A according to Example 2. Samples were taken at the indicated time points and the amount of melted flufenamide dissolved was determined by HPLC. The y-axis shows an amount of melphalan flufenamide in mg / ml.
[0027] Figs. 2A-E contain graphs of the rate of dissolution rate of lyophilized fluphenamide melphalan in the presence of excipients as indicated in the figures by method A according to Example 2. Samples were taken at the indicated time points and the amount of dissolved flufenamide melphalan was determined by HPLC. The x-axis shows the amount of melphalan flufenamide in mg / ml.
[0028] Fig. 3 is a graph of measurement of the speed of dissolution of melphalan flufenamide without excipients by method B according to Example 2. Samples were taken at the indicated time points and the amount of melphalan flu-phenamide dissolved was determined by HPLC. The x-axis shows the amount of melphalan flufenamide in mg / ml.
[0029] Figs. 4A-E contain graphs of the rate of dissolution rate of lyophilized fluphenamide melphalan in the presence of excipients as indicated in the figures by method B. Samples were taken at the indicated time points and the amount of dissolved melphalan flufenamide was determined by HPLC. The x-axis shows the amount of melphalan flufenamide in mg / ml.
[0030] Figs. 5 contains graphs of dissolution rate measurements as follows, A: lyophilized fluphenamide melphalan free of Polysorbate 80; B lyophilized flufen-mida melphalan in the presence of 10% Polysorbate 80; C melphalan flufenamide lyophilized in the presence of 50% Polysorbate 80; D lyophilized melphalan flufenamide in the presence of 100% Polysorbate 80. Quantities are relative to the amount of melphalan flufenamide. The x-axis shows the amount of melted flufenamide dissolved relative to the internal standard as determined using HPLC.
[0031] Fig. 6 is a photograph of glass tubes with flufenamide melphalan (J1) which, following lyophilization, is dissolved in a concentration of 1 mg / mL in a 5% glucose solution containing 50% (mol) of Polysorbate 80 (left) and without Polysorbate 80 (right).
[0032] Fig. 7 contains structural formulas for melphalan flufenamide (ethyl ester-L-melphalanyl-Lp-fluorphenylalanine), isopropyl ester of L-melphalanyl-Lp-fluophenylalanine (JV28), ethyl ester L-prolinyl-L-melphalanyl-Lp-fluorphenyl ). Detailed description of the invention
[0033] Non-lyophilized cytotoxic dipeptides or pharmaceutically acceptable salts thereof may have a low solubility in aqueous solutions, which may require the use of organic solvents, such as DMA (dimethylacetamide), to dissolve said dipeptides or pharmaceutically acceptable salts of themselves. Thus, when a cytotoxic dipeptide is to be administered to a patient, the first substance must be dissolved in an organic solvent, such as DMA, and thus diluted in an infusion solution prior to administration to the patient. By this method the patient is exposed to organic solvents, the exposure of which can be dangerous to the patient. Also, the organic solvent can destroy medical devices used for administering melphalan flufenamide to patients, such as cancer patients.
[0034] The present inventors have now surprisingly found that when certain cytotoxic dipeptides or pharmaceutically acceptable salts thereof are lyophilized in the presence of an excipient, the lyophilized pharmaceutical preparation can have an even greater solubility in a physiologically acceptable solution. In fact, the solubility can be so high that the step of dissolving the cytotoxic dipepid or pharmaceutically acceptable salt thereof in an organic solvent can be omitted and the cytotoxic dipeptide can be directly dissolved in a physiologically acceptable aqueous solution and administered to a patient. Preferably, said cytotoxic dipeptide is melphalan flufenamide or a pharmaceutically acceptable salt thereof.
[0035] In previous preparations, melphalan flufenamide was obtained from the synthesis as a white powder in crystalline form. This crystalline form can only be dissolved in a highly acidic aqueous solution, which for practical manufacturing purposes is impossible. The presence of excipients as such did not sufficiently improve solubility. Thus, previous melphalan flufenamide was instead dissolved in DMA (dimethylacetamide) in a glucose solution. The preparation is viable, but it is unstable: 7% degradation / h. In addition, dimerization occurs and the solution turns light yellow. This preparation was, however, unreliable and the rate of polymerization varied in an unacceptable manner.
Consequently, there is a need to identify alternative ways of providing a preparation comprising melphalan flufenamide or a pharmaceutically acceptable salt thereof that is soluble with increased stability. In addition, the preparation must be soluble in water to avoid negative problems of having an organic solvent in the product that is provided to the patient (such as DMA). One aspect of the present invention is a freeze-dried pharmaceutical preparation comprising (i) melphalan flufenamide, or a pharmaceutically acceptable thereof; and (ii) at least one excipient selected from the group comprising a polysorbate; a polyethylene glycol; β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; Cremofor EL; dimethyl sulfoxide; D-mannitol; Trealose; Sucrose; and an amino acid.
[0037] In an embodiment of this aspect, said excipient is selected from the group comprising Polysorbate 80; PEG 400; lactose; benzilic alcohol; disodium succinate; propylene glycol; PEG 300; Cremofor EL; Dimethyl sulfoxide; D-mannitol; Trealose; Sucrose; and histidine.
[0038] In another embodiment of this aspect, said melphalan flufenamide is melphalan flufenamide hydrochloride (J1). In another aspect of the invention, a pharmaceutical preparation is provided comprising: (iii) melphalan flufenamide hydrochloride (J1); and (iv) at least one excipient selected from the group comprising a polysorbate; u polyethylene glycol; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutildter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; Cremofor EL; dimethyl sufoxide; D-mannitol; Trealose; Sucrose; and an amino acid.
[0039] In an embodiment of this aspect, said at least one excipient is a polysorbate or polyethylene glycol.
[0040] In another embodiment of this aspect, said at least one excipient is Polysorbate 80.
[0041] In another embodiment of this aspect, said at least one excipient has surfactant properties. Such properties can increase the stability of the lyophilized pharmaceutical preparation. Said at least one excipient having surfactant properties can be polysorbate or polyethylene glycol, such as Polysorbate 80 or PEG400.
[0042] In another embodiment of this aspect, the preparation comprises fluoramide melphalan chlorate (J1) and the excipient Polysorbate 80. The presence of the excipient Polysorbate 80 can increase the stability of the lyophilized pharmaceutical preparation. In addition, the final preparation can be free or essentially free of organic solvents and thus less toxic.
[0043] The invention provides a lyophilized preparation that is stable in dry form and soluble in an aqueous solution without the presence of an organic solvent. While it was previously possible to prepare a lyophilized preparation of melphalan flufenamide alone, this preparation dissolved very slowly in aqueous solutions compared to the time of degradation. Incorporation of an excipient in the preparation of lyophilized flufenamide melphalan (through the initial solution in an organic solvent) improves the reconstitution time considerably, but does not significantly alter the stability of reconstituted flufenamide melphalan. As a result, the window time for reconstituted flufenamide melphalan is increased, and this improves patient treatments, for example, by allowing for lower infusion rates where necessary. A preparation "without the presence of an organic solvent" can include trace amounts of organic solvent, typically less than 0.5% (w / w).
[0044] The lyophilized pharmaceutical preparation of melphalan flufenamide or a pharmaceutically acceptable salt thereof as described herein is a white powder, powdery in contrast to a non-lyophilized flufenamide melphalan or a pharmaceutically acceptable salt thereof, which may be in the in the form of a dense, slightly yellowish powder.
[0045] Typically, lyophilization comprises four steps, pre-treatment, freezing, primary drying, and secondary drying. In the pre-treatment step, the substances to be lyophilized are made ready for lyophilization, for example, by preparing a solution having the desired concentration or mixing the substance with additional components in order to obtain an acceptable result. The freezing step can be done in a freeze-dried bottle in an ice bath, for example, by mechanical refrigeration, dry ice and methanol, or liquid nitrogen. Freeze drying machines are available for large-scale freeze drying. Freezing temperatures are usually between -50 ° C and -80 ° C.
[0046] In the primary drying step, the pressure is reduced to the variation of a few millibars, and heating can be provided for the water to sublimate from the material. The amount of heat required can be calculated using the latent heat of sublimation sublimation molecules. The length of this period depends, but it can last for days in order to preserve the structure of the materials.
[0047] The purpose of the final secondary drying step is to remove any molecule from unfrozen water. In this phase, the temperature can be as high as above 0 ° C, to break any physical-chemical interactions that have formed between the water molecules and the frozen material.
[0048] In the context of the present invention, it is to be understood that melphalan flufenamide or a pharmaceutically acceptable salt thereof, is lyophilized. The term "a lyophilized pharmaceutical preparation of a flufenamide melphalan or a pharmaceutically acceptable salt thereof", is thus understood to mean that flufenamide melphalan or a pharmaceutically acceptable salt thereof is lyophilized.
[0049] Additional aspects of the present invention provide lyophilized fluphenamide melphalan or a pharmaceutically acceptable salt thereof, a kit of parts comprising fluoramide tai melphalan, methods for the preparation of fluoramide tai melphalan or a pharmaceutically acceptable salt thereof, compositions such lyophilized fluphenamide melphalan or a pharmaceutically acceptable salt thereof and uses thereof.
[0050] "Freeze-dried", "freeze-dried" etc. can, in the present context, be used in a way that can be changed with "freeze-dried", "freeze dried" etc.
[0051] Examples of cytotoxic dipeptides that can be lyophilized as described herein are disclosed in W001 / 06367. The N-terminus of a molecule should preferably not be protected as an amide or carbamate. This means that FU in formula I here may preferably not be protected as an amide or carbamate. This means that FU in formula I here should preferably not be a protecting group, such as formyl, acetyl or proprionyl, or benzoyl, as the protected form of the compound in general has a lower cytotoxic activity than the corresponding free form. Natural amino acids refer to the amino acids that are normally existing and exercising their functions in living organisms. Modified amino acids refer to amino acids that in some ways have been modified in a different chemical structure and chemical composition than a natural amino acid. An example of a natural amino acid is proline. Examples of aromatic amino acids are phenylalanine, tyrosine, tryptophan, and histidine.
[0052] Cytotoxic dipeptides, such as melphalan flufenamide, can also contain unnatural proportions of atomic isotopes in one or more of their atoms. For example, compounds can be radiolabeled with radioactive isotopes, such as, for example, tritium (3H), deuterium (2H), iodine-125 (125l) or carbon-14 (14C). The cytotoxic melphalan dipeptide clearly differs from melphalan: • Difference in structure (melphalan flufenamide is an ethyl ester at the C-terminal instead of the carboxylic acid in melphalan. Melfalan is thus a dipolar ion (zwitteri-on), but melphalan flufenamide not). • Difference in size (melphalan flufenamide is dipeptide, that is, approximately twice the size of melphalan). • Difference in lipophilicity, where melphalan flufenamide is clearly more lipophilic. • Difference in stability in aqueous solutions. Melfalan is 10,000 times more stable in aqueous solutions compared to J1. J1 is rapidly hydrolyzed in water. • Difference in degradation pathways. The main degradation pathway in honey-phalanflufenamide involves hydrolysis in the ethyl ester, while the main degradation in melphalan is related to the reactivity of the (chlorine) alkyl groups.
[0053] Based on, but not limited to the above differentiations, it is clear that teachings in melphalan, and in particular preparations and formulations thereof, do not apply melphalan flufenamide and preparations and formulations thereof.
[0054] The inclusion of at least one excipient (such as Polysorbate 80 with its surfactant properties) provides lyophilized preparation that is stable as well as soluble in water without the presence of an organic solvent at a sufficient rate compared to the rate of degradation, and it is thus useful in therapy and less toxic.
[0055] The lyophilized pharmaceutical preparation according to the invention can contain only melphalan flufenamide or a pharmaceutically acceptable salt thereof, or a mixture of melphalan flufenamide with one or more different cytotoxic dipeptides or pharmaceutically acceptable salts thereof. In addition, the lyophilized pharmaceutical preparation may contain a mixture of two or more different pharmaceutically acceptable salts.
[0056] One aspect of the invention is a lyophilized pharmaceutical preparation, comprising (i) melphalan flufenamide; and (ii) a combination of two or more excipients selected from the group comprising a polysorbate; a polyethylene glycol; β-cyclodextrin; α- cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutildter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; Cremofor EL; Dimethyl sulfoxide; D-mannitol; Trealose; Sucrose; and an amino acid.
[0057] Still an aspect of the invention is a lyophilized pharmaceutical preparation, comprising: (i) melphalan hydrochloride flufenamide (J1); and (ii) a combination of two or more excipients selected from the group comprising a polysorbate; a polyethylene glycol; β-cyclodextrin; α- cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutyl-ter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose; and an amino acid.
[0058] In an embodiment of this aspect, said combination of excipients is a mixture of Polysorbate 80 and PEG400.
[0059] Pharmaceutically acceptable salts for all aspects of the present invention can be, for example, an acid addition salt of a compound described here that is sufficiently basic, for example, an acid addition salt with, for example, an inorganic acid or organic, for example, hydrochloric, bromide, nitric, methanesulfonic, sulfuric, phosphoric, trifluoroacetic, sulphonic para-toluene, sulphonic 2-mesitylene, citric, acetic, tartaric, fumaric, lactic, succinic, malolic , malonic, maleic, 1,2-ethanedisulfonic, adipic, aspartic, benzenesulfonic, benzoic, ethanesulfonic or nicotinic.
[0060] In this document, when the term "fluphenamide melphalan" is used, it is also intended to include pharmaceutically acceptable salt (s) thereof, even if this is not explicitly attested.
[0061] As mentioned above, when melphalan flufenamide or a pharmaceutically acceptable salt thereof is lyophilized in the presence of a pharmaceutically acceptable excipient, such as any selected polysorbate; a polyethylene glycol; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutyl-ter-β-cyclodextrin; lactose; benzilic alcohol; disodium suction; propylene glycol; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose; and an amino acid; an unexpected high increase in the solubility of the lyophilized pharmaceutical preparation can be obtained, which allows for the direct dissolution of the lyophilized fluphenamide melphalan in an aqueous solution, such as a physiologically acceptable solution. This is in contrast to a non-lyophilized fluphenamide melphalan which cannot be dissolved directly in an aqueous solution but which must first be dissolved in an organic solvent before dilution in an aqueous solution. There is thus provided a lyophilized pharmaceutical preparation comprising melphalan flufenamide or a pharmaceutically acceptable salt thereof, wherein melphalan flufenamide is lyophilized in the presence of an excipient. Preferably, said excipient is selected from polysorbate or polyethylene glycol, such as Polysorbate 80 or PEG400.
[0062] Melfalana flufenamide or a pharmaceutically acceptable salt thereof can be lyophilized in the presence of one or more of an excipient (for example, one, two, three, four, five or more excipients). Examples of excipients that can be used as described herein include, without limitation, polysorbates such as Polysorbate 20, Polysorbate 40, Polysorbate 60, and Polysorbate 80; polyethylene glycols such as PEG 400 and PEG300; β-cyclodextrin, α-cyclodextrin, sulfobutylether- β-cyclodextrin, hydroxypropyl-β-cyclodextrin, lactose, benzyl alcohol, di-sodium succinate, propylene glycol, Cremophor EL, dimethi sulfoxide, D-mannitol, trehalose, sucrose and amino acids such as sucrose and amino acids histidine.
[0063] In one aspect of the invention, the excipient is selected from any of Polysorbate 80, PEG400; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutildter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; PEG300; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose; and histidine.
[0064] In one aspect of the invention, the excipient is selected from Polysorbate 80; PEG400; lactose; benzilic alcohol; disodium succinate; propylene glycol; PEG300; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose; and histidine; or a combination of two or more of said excipients.
[0065] In an embodiment of this aspect, the excipient is selected from Polysorbate 80 and PEG400, or a combination of said two excipients.
[0066] The amount of excipient such as Polysorbate 80, PEG400 or β-cyclodextrin, is typically about 10-100% by weight of the amount of melphalan flufenamide, such as 100, 90, 80, 70, 60, 50, 40, 30, 20 or 10% by weight of the amount of melphalan flufenamide.
[0067] In yet another aspect of the invention, the amount of excipient, such as Polysorbate 80, PEG 400 or β-cyclodextrin, is typically about 10-50% by weight of the amount of melphalan flufenamide, such as 100, 90, 80 , 70, 60, 50, 40, 30, 20 or 10% by weight of the amount of melphalan flufenamide.
[0068] In an embodiment of this aspect, the excipient represents Polysorbate 80 or PEG 400, and the amount thereof is typically about 10-50% by weight of the amount of melphalan flufenamide, such as 100, 90, 80, 70, 60 , 50, 40, 30, 20 or 10% by weight of the amount of melphalan flufenamide.
[0069] Still an aspect of the invention is a lyophilized pharmaceutical preparation comprising: (i) melphalan flufenamide, or a pharmaceutically acceptable salt thereof; and (ii) at least one excipient selected from the group comprising
[0070] Polysorbate 80, PEG400, β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutildter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; PEG300; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose; and histidine; wherein the amount of excipient is about 10-100% by weight of melphalan flufenamide.
[0071] In an embodiment of this aspect, at least one excipient selected from Polysorbate 80 and PEG 400.
[0072] In another modality of this aspect, melphalan flufenamide is represented by melphalan hydrochloride flufenamide (J1).
[0073] Still an aspect of the invention is a lyophilized pharmaceutical preparation comprising (i) melphalan flufenamide, or a pharmaceutically acceptable salt thereof; and (ii) at least one excipient selected from the group comprising Polysorbate 80; PEG400; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutildter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; PEG300; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose; and histidine; wherein the amount of excipient is about 10-50% by weight of fluphenamide melphalan hydrochloride (J1).
[0074] In an embodiment of this aspect, at least one excipient selected from Polysorbate 80 and PEG400.
[0075] In another aspect of this aspect, melphalan flufenamide is represented by melphalan hydrochloride flufenamide (J1). Yet another aspect of the invention is a lyophilized pharmaceutical preparation comprising (i) melphalan hydrochloride flufenamide (J1); and (ii) at least one excipient selected from the group comprising Polysorbate 80; PEG400; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextria; sulfobutildter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; PEG300; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose; and histidine; wherein the amount of the excipient is about 10-100% by weight of melphalan flufenamide hydrochloride (J1).
[0076] In an embodiment of this aspect, at least one excipient is selected from Polysorbate 80 and PEG400. A further aspect of the invention is a freeze-dried pharmaceutical preparation comprising: (i) melphalan hydrochloride flufenamide (J1); and (ii) at least one excipient selected from the group comprising Polysorbate 80; PEG400; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutyl-ter-β-cyclodextrin; lactose; benzilic alcohol; dysodic succinate; propylene glycol; PEG300; Cremofor EL; dimethyl sulfoxide; D-mannitol; Trealose; Sucrose; and histidine; wherein the amount of excipient is about 10-50% by weight of fluphenamide melphalan hydrochloride (J1).
[0077] In an embodiment of this aspect, at least one excipient is selected from Polysorbate 80 and PEG400.
[0078] In an embodiment of the invention, the amount of excipient, such as Polysorbate 80 or PEG400, can even be the clinically acceptable amount.
[0079] In an embodiment of the invention, the amount of excipient, such as Polysorbate 80 or PEG400, can be even the clinically acceptable amount.
[0080] When used as the sole excipient, the amount of Polysorbate 80 or PEG400 is, for example, about 50% by weight of the amount of melphalan hydrochloride flufenamide (J1).
[0081] One aspect of the invention is a combination of the Polisor-bato 80 and PEG400 excipients.
[0082] One aspect of the invention is a combination of the excipients Polisor-bato 80, PEG400 and β-cyclodextrin, such as 80% by weight of Polysorbate 80, 80% by weight of PEG400 and 50% by weight of β-cyclodextrin, from amount of flufenamide melphalan. A lyophilized pharmaceutical preparation of a melphalan derivative or a pharmaceutically acceptable salt thereof, can according to the invention comprise one or more melphalan derivative (s) or a pharmaceutically acceptable salt (salts) of the ) same (s), and one or more excipients as defined herein.
[0083] As mentioned above, an effect of the presence of an excipient during lyophilization is that the resulting lyophilized pharmaceutical preparation, comprising melphalan flufenamide, has an increased solubility in aqueous solutions, such as a physiologically acceptable solution, compared to when melphalan flufenamide is lyophilized without an excipient as described herein. In particular, the solubility in aqueous solutions of melphalan flufenamide when lyophilized in the presence of an excipient (s) is higher compared to the solubility of the non-lyophilized product. This increased solubility of melphalan flufenamide, particularly when lyophilized in the presence of an excipient described herein, compared to the non-lyophilized product, has substantial advantages when it comes to the administration of melphalan flufenamide to a patient.
[0084] Due to the low solubility of non-lyophilized fluphenamide melphalan in aqueous physiologically acceptable solutions used for drug administration to a patient, it is necessary to first dissolve the non-lyophilized melphalan flufenamide in an organic solvent, such as DMA. Melfalana flufenamide is then always stored dissolved in DMA. It has not previously been possible to directly dissolve the fluphenamide melphalan in an aqueous solution, but organic solvents had to be used. Once dissolved in the organic solvent, this solution of melphalan flufenamide and organic solvent can be dissolved in physiologically acceptable solutions for administration to a patient.
[0085] Since melphalan flufenamide is very toxic, in order to minimize the exposure of doctors to such drugs, special devices for transferring drugs after dissolving in organic solvents for the solution for administration, are used. These transfer devices are always plastic tubes comprising polycarbonate. However, such tubes are sensitive to and can be destroyed by organic solvents, such as DMA. Thus, in cases where the drug to be administered is dissolved in such an organic solvent, it may not be possible to use the transfer device, and the dissolved drug instead has to be directly added to the physiologically acceptable solution used for administration just before the time of administration to the patient. This can be dangerous for medical staff, who are then at risk if exposed to the toxic drug.
[0086] As mentioned above, lyophilization of melphalan flufenamide increases its solubility in physiologically acceptable solutions. This increase can be even more pronounced when melphalan flufenamide is lyophilized in the presence of one or more excipients. As described herein, when melphalan flufenamide is lyophilized in the presence of an excipient as disclosed herein, the solubility of mel phalanflufenamide can be increased, compared to un lyophilized melphalan flufenamide. The use of an organic solvent, such as DMA, to first dissolve melphalan flufenamide can be avoided.
[0087] Melfalana flufenamide which has been lyophilized in the presence of at least one excipient, such as a polysorbate which, for example, can be Polisor-bato 80; a polyethylene glycol which, for example, can be PEG400 or PEG300; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutildter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; Cremofor EL; dimethyl sulfoxide; D-mannitol; Trealose; Sucrose; or an amino acid tai like histidine; or a combination of two or more of these excipients; can be directly dissolved in a physiologically acceptable solution, such as about 4.5-5.5 p%, for example, about 5%, glucose solution or aqueous NaCI solution (for example, about 0, 9 p% NaCI). Thus, devices comprising polycarbonate and which are used for the administration of melphalan flufenamide are possible to use, minimizing the risk for medical staff exposure to the drug. Also, in this form of administration, toxic DMA to the patient is avoided. This allows for direct preparation of the solution comprising melphalan flufenamide in a concentration suitable for administration to the patient. Alternatively, a concentrated solution comprising a lyophilized pharmaceutical preparation of melphalan flufenamide in a physiologically acceptable solution can first be prepared and then transferred to the infusion bag using the commonly used transfer devices.
[0088] Also, when melphalan flufenamide is dissolved in DMA, an adduct between melphalan flufenamide and DMA can be formed. By using a lyophilized pharmaceutical preparation provided according to the invention, it is possible to dissolve the lyophilized melphalan flufenamide directly in a physiologically acceptable solution, first avoiding the dissolution of melphalan flufenamide in DMA. Thus, the formation of DMA-melphalan flufenamide adducts can be avoided and neither the adduct nor DMA has to be administered to the patient.
[0089] There is also a pharmaceutical composition comprising a lyophilized pharmaceutical preparation of melphalan flufenamide or a pharmaceutically acceptable salt thereof as defined herein, optionally obtained by the method for preparing such a lyophilized preparation disclosed herein. Such a pharmaceutical composition may further comprise a physiologically acceptable solution, such as an aqueous NaCI (for example, about 0.9 p%) or a glucose solution (for example, about 4.5-5.5 p% , such as about 5 wt%, glucose). This pharmaceutical composition can be a concentrated solution intended for dilution prior to administration to a patient or as a solution allowing direct administration to a patient.
[0090] Due to the increased solubility of melphalan flufenamide after lyophilization in the presence of one or more excipients as described herein, it is possible to prepare a solution of melphalan flufenamide dissolved, such as a pharmaceutical composition comprising a melphalan flufenamide or pharmaceutically acceptable salt thereof, which is substantially free of organic solvents such as DMA, dichloromethane, tetrahydrofuran, 2-methyl tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethyl sulfoxide, dioxane, diethyl ether, acetic acid, n-butanol, isopropanol, n-propanol, tert-butanol, sec-butanol, methanol, ethanol, and acetic acid. By "substantially free" it is intended in this document that the pharmaceutical composition comprises only trace amounts of an organic solvent, such as less than about a total of about 0.1 p% of an organic solvent. In one aspect, the lyophilized preparation or pharmaceutical composition does not contain any measurable amounts of an organic solvent. Such preparations can be less toxic and thus more tolerated by a patient, that is, giving less side effects such as vomiting, nausea or other general symptoms when infused.
[0091] In one aspect of the invention, a lyophilized pharmaceutical preparation as described herein is provided, which is free, or substantially free of organic solvents.
The pharmaceutical composition may consist of a lyophilized pharmaceutical preparation as disclosed herein, comprising melphalan flufenamide or pharmaceutical salt thereof, and the physiologically acceptable solution, such as a glucose solution. As disclosed above, the melphalan derivative can be melphalan flufenamide or a mixture of melphalan flufenamide and one or more different cytotoxic dipeptides, or lyophilized together or separately.
[0093] The pharmaceutical composition can be obtained by dissolving melfa-lana flufenamide or a pharmaceutical salt thereof in a physiologically acceptable solution. A method for preparing a pharmaceutical composition comprising the step of dissolving the lyophilized pharmaceutical preparation comprising melphalan flufenamide or a pharmaceutically acceptable salt thereof in a physiologically acceptable solution is then also provided here.
[0094] The phrase a "physiologically acceptable solution" is defined herein, it is an aqueous solution, such as NaCI solution (such as about 0.9 p-% NaCI) or glucose solution, such as about 4.5 -5.5 p-% glucose, for example, 5 p-%, or another physiologically acceptable solution. Any such solution can optionally be buffered.
[0095] A pharmaceutical composition comprising lyophilized melphalan flufenamide and a physiologically acceptable solution for direct administration to a patient, generally comprises melphalan flufenamide in a concentration of about 1 mg / ml or less, such as about 0.2 mg / ml. However, the pharmaceutical composition can comprise melphalan flufenamide at a concentration of up to about 4 mg / mL for dilution in a physiologically acceptable solution prior to administration to a patient.
[0096] One aspect of the invention provides a method for preparing a lyophilized pharmaceutical preparation, where: a) melphalan flufenamide, or a pharmaceutically acceptable salt thereof, is dissolved in an organic solvent to obtain a melphalan flufenamide solution; b) water is added to the melphalan flufenamide solution in order to obtain an aqueous melphalan flufenamide solution, in a concentration of about 0.2-3.0 mg / mL; c) at least one excipient selected from the group comprising a polysorbate; a polyethylene glycol; β-cyclodextrin; α-cyclodextrinal; hydroxypropyl-β-cyclodextrin; sulfobutyl-ter-β-cyclodextrin; lactose; benzilic alcohol; dysodic succinate; propylene glycol; Cremofor EL; dimeithl sulfoxide; D-mannitol; Trealose, Sucrose and an amino acid are added to the melphalan flufenamide solution; and d) the aqueous melphalan flufenamide solution containing excipient (s) is subjected to lyophilization.
[0097] In a modality of this aspect, a method is provided, where: a) melphalan flufenamide, or a pharmaceutically acceptable salt thereof, is dissolved in an organic solvent; b) water is added to the solution obtained in step a) in order to obtain a solution of the said melphalan flufenamide or a pharmaceutically acceptable salt thereof, in a concentration of about 0.2-3.0 mg / ml; c) at least one excipient selected from the group comprising a polysorbate; a polyethylene glycol; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutyl-ter-β-cyclodextrin; lactose; benzilic alcohol; dysodic succinate; propylene glycol; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose and an amino acid are added to the solution obtained in step b); and d) the solution obtained in step c) is subjected to lyophilization.
[0098] The organic solvent can be selected from any of ethanol, ethanol containing acid, glycerin, propylene glycol, benzyl alcohol, dimethylacetamide (DMA), N-methyl-2-pyrrolidone, isopropanol, n-butanol, tert-butanol, methyl tert-butyl ether, propylene glycol, dimethyl sulfoxide, tetrahydrofuran, 2-methyl tetrahydrofuran, acetone, dimethylformamide, acetonitrile, dioxane, acetic acid, lactic acid, propionic acid, n-butanol, isopropanol, n-propanol, tert -butanol, sec-butanol, methanol, and a mixture of ethanol and water. Preferably, said organic solvent is ethanol.
[0099] The excipient can be selected from the group comprising Polysorbate 801 PEG400; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutyl-ter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; PEG 300; Cremofor EL; dimethyl sufoxide; D-mannitol; Trealose; Sucrose; and histidine. Preferably, said excipient is selected from Polysorbate 80 and PEG 400. The melphalan flufenamide in said methods is preferably melphalan flufenamide hydrochloride (J1). One aspect of the present invention is a method for the preparation of a lyophilized pharmaceutical preparation as described herein, where a) melphalan flufenamide, or a pharmaceutically acceptable salt thereof, is dissolved in an organic solvent; b) water is added to the solution obtained in step a) in order to obtain a solution of the said melphalan flufenamide or a pharmaceutically acceptable salt thereof, in a concentration of about 0.2-3.0 mg / ml; c) at least one excipient as defined herein, is added to the solution obtained in step b); and d) the solution obtained in step c) is subjected to lyophilization.
[00100] Preferably, said organic solvent is ethanol.
[00101] One aspect of the present invention is a method for the preparation of a lyophilized pharmaceutical preparation as described herein, where a) flufenamide melphalan hydrochloride (J1) is dissolved in an organic solvent; b) water is added to the solution obtained in step a) in order to obtain a solution of the said melphalan hydrochloride flufenamide (J1), or a pharmaceutically acceptable salt thereof, in a concentration of about 0.2-3, 0 mg / ml; c) at least one excipient as defined herein, is added to the solution obtained in step b); and d) the solution obtained in step c) is subjected to lyophilization.
[00102] Examples of organic solvents useful for dissolving melphalan flufenamide or a pharmaceutically acceptable salt thereof in step a), can be any one selected from ethanol, ethanol containing acid, glycerin, propyl-glycol, benzyl alcohol, dimethylacetamide (DMA), N-methyl-2-pyrrolidone, isopropanol, n-butanol, tert-butanol, methyl tert-butyl ether, propylene glycol, dimethylsulfoxide, tetrahydrofuran, 2-methyl tetrahydrofuran, acetone, dimethylformamide, acetonitrile, dioxane, acetic acid, lactic acid, propionic acid, n-butanol, isopropanol, n-propanol, tert-butanol, sec-butanol, methanol, and a mixture of ethanol and water.
[00103] An aspect of the present invention is a method for the preparation of a lyophilized pharmaceutical preparation as described herein, where a) melphalan flufenamide, or a pharmaceutically acceptable salt thereof, is dissolved in an organic solvent selected from any of ethanol, ethanol containing acid, glycerin, propylene glycol, benzyl alcohol, dimethylacetamide (DMA), N-methyl-2-pyrrolidone, isopropanol, n-butanol, tert-butanol, methyl tert-butyl ether, propylene glycol, dimethylsulfoxide, tetrahydrofuran, 2-methyl tetrahydrofuran, acetone, dimethylformamide, acetonitrile, dioxane, acetic acid, lactic acid, propionic acid, n-butanol, isopropanol, n-propanol, tert-butanol, methanol, and a mixture of ethanol and water; b) water is added to the solution obtained in step a) in order to obtain a solution of the said melphalan flufenamide or a pharmaceutically acceptable salt thereof, in a concentration of about 0.2-3.0 mg / ml; c) at least one excipient, as defined herein, is added to the solution in step b); and d) the solution obtained in step c) is subjected to lyophilization.
[00104] One aspect of the present invention is a method for the preparation of a lyophilized pharmaceutical preparation as described herein, where a) flufenamide melphalan hydrochloride (J1), is dissolved in an organic solvent selected from any of ethanol, acid-containing ethanol, glycerin, propylene glycol, benzyl alcohol, dimethylacetamide (DMA), N-methyl-2-pyrrolidone, isopropanol, n-butanol, tert-butanol, methyl tert-butyl ether, propylene glycol, dimethylsulfoxide, tetrahydrofuran, 2-methyl tetrahydrofuran, acetone, dmethylformamide, acetonitrile, dioxane, acetic acid, lactic acid, propionic acid, n-butanol, isopropanol, n-propanol, tert-butanol, sec-butanol, methanol, and a mixture of ethanol and Water; b) agia is added to the solution obtained in step a) in order to obtain a solution of the said melphalan hydrochloride flufenamide (J1), or a pharmaceutically acceptable salt thereof, in a concentration of about 0.2-3.0 mg / ml; c) at least one excipient as defined herein, is added to the solution obtained in step b); and d) the solution obtained in step c) is subjected to lyophilization.
[00105] One aspect of the present invention is a method for the preparation of a lyophilized pharmaceutical preparation as described herein, where a) melphalan flufenamide hydrochloride (J1) is dissolved in an organic solvent; b) water is added to the solution obtained in step a) in order to obtain a solution of the said melphalan hydrochloride flufenamide (J1), in a concentration of about 0.2-3.0 mg / mL; c) at least one excipient, as defined herein, is added to the solution obtained in step b); and d) the solution obtained in step c) is subjected to lyophilization; wherein at least one excipient is selected from Polysorbate 80 and PEG400.
[00106] When acid-containing ethanol is used to dissolve melphalan flu-phenamide or a pharmaceutically acceptable salt thereof in step a) in the above method, the acid can be HCI, in a concentration of, for example, 5-20 mM, or the HCI concentration can, for example, be 10 mM, in ethanol.
[00107] When melphalan flufenamide or a pharmaceutically acceptable salt thereof is dissolved in ethanol and water, the concentration of ethanol can be about 10-100 vol-%, such as 10-90 vol-%, 50-90 vol-% , about 70 vol-%.
[00108] The water used to dissolve and / or dilute samples of a lyophilized pharmaceutical preparation according to the present invention, is sterile or purified water, or water for injection (WFI).
[00109] When ethanol is used to dissolve melphalan flufenamide or pharmaceutically acceptable salt thereof, the solution obtained in step a) is diluted in step b) so that the concentration of ethanol is about 2% -100% by volume, such as about 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100%, or such as 5-15%, or such as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15%. Typically, the ethanol concentration after the dilution of step b) is about 9%.
[00110] The solution obtained in step b) can be sterilized by filtration before the lyophilization step c).
[00111] The freeze drying step c) comprises the typical primary and secondary freezing and drying steps as described herein. Information about how lyophilization is done can be found, for example, in Rey, L. and May, J. Freeze Drying / Lyophilization of Pharmaceutical and Biological Products (2010), ISBN 978-1439B2575-4. In the freezing step, the sample is, for example, frozen in an ice-acetone bath at a temperature of about -70 ° C to -90 ° C, such as about -70 ° C, -75 ° C, -78 ° C, -80 ° C, -82 ° C, -85 ° C, -88 ° C or -90 ° C, for example, for 10 minutes to 120 minutes.
[00112] Alternatively, the sample can be frozen in a freezer at a temperature of about -14 ° C to -25 ° C, such as -14 ° C, -16 ° C, -18 ° C, -20 ° C , - 22 ° C or -25 ° C, for example, for about 10 min to 24 hours. It is also possible to freeze the sample in liquid nitrogen.
[00113] Step c) can be done by applying conventional techniques for lyophilization, see, for example, Rey, L. and May, J. Freeze Drying / Lyophilization of Pharma-ceutical and Biological Products (2010), ISBN 978- 1439B2575-4.
[00114] For example, in the primary drying step, the pressure can be reduced to about 0.1 mbar (10000 mPa) at 50 mbar (5,000,000 mPa), such as 1 mbar (100,000 mPa) at 10 mbar (1,000,000 mPa). The temperature is typically below 0 ° C, such as -50 to 0 ° C, or -20 to -1 ° C, for example, -50, -40, -30, -20, - 10, or -5 ° Ç. This phase can, for example, last for 4 hours to 48 hours, for example, 12 hours to 24 hours.
[00115] In the final secondary drying step, when most of the water has been evaporated, the temperature can be as in the primary drying step or above 0 ° C.
[00116] When one or more excipients as defined herein are to be present during lyophilization, these may be additional in step b) before or after diluting the solution obtained in step a) and before making lyophilization. Excipients can be added in powder form but are generally added as an aqueous solution. Excipients can thus be present during lyophilization.
[00117] The present invention is also directed to a lyophilized pharmaceutical preparation as defined herein obtained by the method disclosed above.
[00118] A kit of parts comprising: (i) a first container comprising a lyophilized pharmaceutical preparation comprising melphalan flufenamide as described herein is also provided here; and (ii) a second container comprising a physiologically acceptable solution, such as a NaCI solution (such as about 0.9 p% NaCI) or a glucose solution, such as about 4.5-5.5 p % glucose solution, for example, about 5 p% glucose solution, or other physiologically acceptable solution.
[00119] Such a kit may also comprise a device for mixing the contents of the two containers with each other and / or for transferring the resulting mixture to a device, such as a pouch comprising a glucose solution, for administration to a patient.
[00120] Such a kit may consist of the first container comprising a lyophilized pharmaceutical preparation comprising melphalan flufenamide as described herein and the second container comprising the physiologically acceptable solution. Melfalan flufenamide in the kit may also be mixed with a pharmaceutically acceptable carrier and / or excipient. An example is 5% glucose with, for example, 1% albumin or another protein or compound. The amount of physiologically acceptable solution can either be a small amount to prepare a concentrated solution of the lyophilized pharmaceutical preparation comprising melfa-lana flufenamide, or a large amount to allow the preparation of a solution having the desired concentration for administration to a patient. Alternatively, the kit may comprise both, a container comprising a physiologically acceptable solution for preparing a concentrated solution of the lyophilized pharmaceutical preparation and a second container, such as an infusion bag, comprising a large amount of a physiologically acceptable solution for preparing more diluted solution for administration to a patient.
[00121] A lyophilized pharmaceutical preparation, pharmaceutical composition or kit provided herein may comprise only melphalan flufenamide or a pharmaceutically acceptable salt thereof as an antitumor agent. However, melphalan flufenamide can also be combined with one or more anti-tumor agents, such as other anti-tumor substances such as gemcitabine, etoposide, doxorubicin or taxanes or other therapeutically effective substances. When combined with other antitumor agents, they can either be mixed with melphalan flufenamide or pharmaceutically acceptable salt thereof prior to lyophilization and consequently lyophilized together with melphalan flufenamide or pharmaceutically acceptable salt thereof or combined with lyophilized flufenamide melphalan or pharmaceutically acceptable salt thereof. after lyophilization, such as in a kit or pharmaceutical composition. Lyophilized flufenamide melfalan can also be mixed with one or more antitumor substances in dry form, even if not lyophilized, after lyophilization of flufenamide melphalan or pharmaceutically acceptable salt thereof.
[00122] Melfalan flufenamide provided here has a cytotoxic activity and can thus be used in the prevention and / or treatment of cancer as described elsewhere elsewhere (see, for example, WO01 / 96367). A reduction in tumor cell survival of these compounds was in WO 01/96367 demonstrated for different hematological and / or solid tumors, for example, lung cancer, myeloma, lymphoma, leukemia, breast cancer, and ovarian carcinoma. In addition, these compounds have been demonstrated in WO 01/96367 to prevent melphalan flufenamide. These compounds can thus be used in the prevention and / or treatment of cancer by reducing tumor growth and / or tumor cell death. The compounds can then be used to cure and / or prolong the survival of patients afflicted with cancer diseases.
[00123] Also provided herein is the lyophilized pharmaceutical preparation, lit or pharmaceutical composition as disclosed and claimed herein, for use as a medicament. The invention is also directed to such a lyophilized pharmaceutical preparation, kit or pharmaceutical composition, for use in the treatment and / or prevention of cancer, such as ovarian cancer, lung cancer, bladder cancer, mesothelioma, multiple myeloma, cancer and / or any other solid or hematological cancer.
[00124] One aspect of the present invention is the use of a freeze-dried pharmaceutical preparation, kit or pharmaceutical composition as disclosed and claimed here, for the preparation of a medicament for the treatment and / or prevention of cancer, such as ovarian cancer , lung cancer, bladder cancer, mesothelioma, multiple myeloma, breast cancer and / or any other solid or hematological cancer.
[00125] Yet another aspect of the present invention provides a freeze-dried pharmaceutical preparation, kit or pharmaceutical composition comprising flufenamide melphalan hydrochloride (J1) in combination with another drug useful in the treatment of cancer, for use in the treatment and / or prevention of cancer , such as ovarian cancer, lung cancer, bladder cancer, mesothelioma, multiple myeloma, breast cancer and / or any other solid or hematological cancer.
[00126] Still an aspect of the present invention is a method for treating and / or preventing cancer, such as ovarian cancer, lung cancer, bladder cancer, mesothelioma, multiple myeloma, breast cancer and / or any other solid or hematological cancer. The method may comprise administering a lyophilized pharmaceutical preparation, a kit or a pharmaceutical composition as provided herein in a therapeutically effective dose to a patient in need thereof. The patient is typically a human or domestic animal.
[00127] Still an aspect of the present invention is a method for treating and / or preventing cancer, such as ovarian cancer, lung cancer, bladder cancer, mesothelioma, multiple myeloma, breast cancer and / or any other solid or haematological cancer, in which the lyophilized pharmaceutical preparation, a kit or a pharmaceutical composition comprising flufenamide melphalan hydrochloride (J1) is provided in a therapeutically effective dose to a patient in need of it, in combination with another useful drug in the treatment of cancer. The patient is typically a human or domestic animal.
[00128] The administration of a lyophilized pharmaceutical preparation, kit or pharmaceutical composition to a patient in need of it can occur by intravenous injections. It is also possible to administer lyophilized fluphenamide melphalan or a pharmaceutical composition comprising such lyophilized fluphenamide melphalan in the body cavities, such as bladder instillation, or in peritoneal or pleural cavities.
[00129] Melfalan flufenamide or a pharmaceutically acceptable salt thereof can be administered in an amount of about 20-130 mg, such as 30-75 mg, for example, 50 mg of total amount of melphalan flufenamide per administration. The pharmaceutical composition or kit provided herein comprising flufenamide mel-phallan may thus have an amount of lyophilized melphalan flufenamide such that this amount can be administered.
[00130] Lyophilized flelfenamide melfalana or a pharmaceutically acceptable salt thereof can be administered daily, every second or third day, weekly, every second, third or fourth week or less as a single high dose (for example, before the transplant) depending on the patient and form of cancer to be treated.
[00131] The word "prevention", as used herein, is intended to include therapy in a patient who has been subjected to chemotherapy against any form of cancer as described herein, and who is subject to continued therapy in order to prevent any metastasis occurring from said cancer.
[00132] Still, an aspect of the present invention provides for the use of an excipient selected from the group consisting of Polysorbate 80; PEG400; β-cyclodextrin; α-cyclodextrin; hydroxypropyl-β-cyclodextrin; sulfobutildter-β-cyclodextrin; lactose; benzilic alcohol; disodium succinate; propylene glycol; PEG300; Cremofor EL; dimethyl sulfoxide; D-mannitol; trehalose; sucrose and histidine. In a lyophilized preparation of melphalan flufenamide, or a pharmaceutically acceptable salt thereof, to decrease the reconstitution time of the lyophilized preparation of melphalan flufenamide, or a pharmaceutically acceptable salt thereof, when reconstituted in an aqueous solvent.
[00133] Said melphalan flufenamide, or a pharmaceutically acceptable salt thereof, is preferably melphalan flufenamide hydrochloride (J1).
[00134] Said excipient is preferably selected from Polysorbate 80 and PEG 400.
[00135] Said melphalan flufenamide or a pharmaceutically acceptable salt thereof is preferably dissolved in ethanol before subjecting said melphalan flufenamide to said excipient.
[00136] In this document "freeze-drying", "freeze-drying", "freeze-drying", "freeze-drying" and the like can be used in a mutable way.
[00137] Polysorbate 80 (having the chemical name Polyoxyethylene 20 sorbitan monooleate and CAS registration number 9005-65-6) is commercially available from, for example, Fluka or Sigma-Aldrich.
[00138] PEG400 has the empirical formula HOCH2 (CH2OCH2) mCH2OH, where m is 8.7, and the average molecular weight is 380-420, and is commercially available from, for example, Fluka or Sigma-Aldrich.
[00139] PEG300 has the empirical formula HOCH2 (CH2OCH2) mCH2OH, where m is 6.4, and the average molecular weight is 285-315, and is commercially available from, for example, Fluka or Sigma-Aldrich.
[00140] Cremofor EL® is a registered trademark sold by Sigma-Aldrich, and is polyoxyethylene castor oil with CAS Registration Number 61791-12-6.
[00141] Exemplary cytotoxic dipeptides that can be used as described here are also disclosed in WO01 / 96367 and may have the formula V
wherein R1 is alkyloxy, cycloalkyloxy, aryloxy, arylalkyloxy, NH2, alkylamino, cycloalkylamino or arylamino; R3 is NH2, OH, O-alkyl, N-alkyl, O-acyl, NH-acyl, N (CH2CH2Cl) 2, NO2, F, CF3 or H; and R4 is a natural or modified cyclic or aromatic amino acid, or H; as well as pharmaceutically acceptable salts thereof.
[00142] Also, cytotoxic peptides that can be used described herein include peptides of formula I or V, where R3 is F. Dipeptides are examples of peptides of formula I or V, where Ri is alkyloxy; F, CF3, H, OH, O-alkyl, NO2, N (CH2CH2Cl) 2, NH-acyl or NH2; and R4 is H.
[00143] Tripeptides are examples of peptides of formula I or V, where Ri is alkyloxy; R is F, CF3, H, OH, O-alkyl, NH-acyl, NO2, N (CH2CH2Cl) 2 or NH2; and R4 is a natural or modified cyclic or aromatic amino acid.
[00144] Melfalana flufenamide, or a pharmaceutically acceptable salt thereof, can be prepared as disclosed in WO 01/96367, the disclosure of which is incorporated by reference. Example 1 of WO 01/96367 discloses a synthetic procedure for making melphalan flufenamide (ethyl ester of L-melphalanyl-Lp-fluorophenylalanine), as well as its hydrochloride salt - melphalan hydrochloride flufenamide J1 (ethyl ester of L-melphalanyl-Lp -fluorfenylalanine, compound J1), the disclosure of which is incorporated herein.
The dipeptide derivatives disclosed in WO 01/96367 can be synthesized from tert-butoxycarbonyl-protected melphalan (Boc) as disclosed herein and can be lyophilized and used as described herein. Also, WO01 / 96367 discloses the preparation of tripeptide derivatives, in which Boc-protected amino acids were coupled to the melphalan containing dipeptide derived when EDC / NMM / HOBt as coupling reagents (EDC is triethylamine or 1- [3-dimethylamino) hydrochloride propyl] -3-ethylcarbodiimide, NMM is N-methylmorpholine and HOBt is 1-hydroxybenzotriazole). Such tripeptide derivatives can be lyophilized and used as described herein.
[00146] Examples of melphalan derivatives that can be lyophilized and used as described herein in all respects include, without limitation, melphalan flufenamide, isopropyl ester of L-melphalanyl-Lp-fluorophenylalanine (JV28), ethyl ester L-prolinyl-L -melfalani-Lp-fluorophenylalanine (J3) (Fig. 7) and pharmaceutically acceptable salts thereof. These compounds are previously disclosed in WO01 / 96367, which also provides methods for their preparation. Melfalana flufenamide, JV28 and J3 can be transformed into melphalan in the body. In WO01 / 96367, these derivatives have been shown to have increased cell death activity against tumors, even when used in concentrations lower than melphalan. In addition, resistance to melphalan can be avoided.
[00147] The invention will be further described by means of the following examples, which do not limit the purpose of the invention. Experimental Section Example 1: Lyophilization of fluphenamide melphalan hydrochloride (J1) under different conditions
[00148] In this experiment, lyophilization of melphalan hydrochloride flufenamide (J1), under various conditions was tested. Example 1A
[00149] Heavy amounts of J1 were dissolved in several volumes of deionized water in an ultrasonic bath with mild heating to have clear solutions. The samples were frozen in a dry ice bath - acetone (-78 ° C, samples A1-A3) or in a freezer at -16 ° C (samples B1-B3). Lyophilization was then conducted for 16 h at a pressure of 1 mbar (100,000 mPa) at room temperature with a dry ice-acetone trap (-78 ° C) between the drying flask and the pump. The visual appearance after drying was as summarized in Table 1. Table 1. Six different solutions of J1 at various freezing concentrations or temperatures.
Example 1B
[00150] Samples of the dry compounds were dissolved in 50% aqueous acetonitrile and analyzed by HPLC (ACE column, C8, 50x3 mm, 10-97% CH3CN in 3 min, 1 ml / min). In one case (J1A1) the aqueous solution was analyzed by HPLC before lyophilization (J1A1-start). Purity after drying was as summarized in Table 2. Table 2. Purity after lyophilization. Tr = retention time
Example 1C
[00151] Then the use of slightly acidic water (for example, 0.01% HC) was tested to increase the speed of dissolution or to first dissolve J1 in ethanol, before adding water (neutral or slightly acidic). Three samples of J1 were prepared by dissolving flufen-wet melphalan (ca 3 mg) in aq. 70% (0.5 ml). The solutions were diluted with 5 mM HCI to give a concentration of 0.4 mg / ml. Since melphalan flufenamide dissolved rapidly in aq. it was not necessary to use an ultrasound bath or heating to have a clear solution. The solutions were then frozen in a dry ice - acetone bath trap (-78 ° C) between the drying flask and the pump. The visual appearance after drying was as summarized in Table 3. Table 3. Three replicates of J1 dissolved in ethanol and acid.
Example 1D
[00152] Two runs of HPLC were performed on each sample: one from the solid compound that can be removed from the bottle and one by dissolving the remainder of the compound in the bottle (table 4). Table 4. Purity after lyophilization.

[00153] In conclusion, by dissolving J1 in 70% ethanol, diluting with 5 mM HCI and lyophilizing, three samples were obtained with purity> 95%. Example 1E
[00154] It was then tested to omit the acid and instead dilute the ethanol with deionized water. Three samples of J1 were prepared by dissolving J1 (ca 3 mg) in aq. 70% (0.5 mL) at room temperature. The solutions were diluted with deionized water to give a concentration of 0.4 mg / mL. The solutions were then frozen in a dry ice-acetone bath (-78 ° C). Lyophilization was then conducted for 16 h at a pressure of 1 mbar at room temperature with a dry ice-acetone trap (-78 ° C) between the drying vial and the pump. The visual appearance after drying was summarized in Table 5 and the purities in Table 6. Table 5. Three replicates of J1 dissolved in ethanol and water.
Table 6. Purity after lyophilization

[00155] By dissolving J1 in 70% ethanol, diluting with water and freeze-drying; three replicates of samples were obtained with the same purity as the starting material. Example 2: Effect of excipients on the dissolution rate of lyophilized fluphenamide melphalan
[00156] In this experiment and effect on the speed of dissolution by adding excipients for the lyophilization process of melphalan hydrochloride flufenamide (J1) was tested. The following excipients have been used, all of which are common formulation agents generally considered safe (GRAS) according to the US Food and Drug Administration (FDA): _ D-mannitol, trehalose and sucrose; _ trizma hydrochloride and L-histidine; _ Polysorbate 80, β-cyclodextrin; J1 was used in all experiments. D-mannitol, was purchased from Sigma no. 33440; D - (+) - trehalise dihydrate, was purchased from Sigma no. T9449-25 g; Trizma hydrochloride, was purchased from Sigma no. T3253-100 g; Β-cyclodextrin hydrate, was purchased from Sigma no. 856088-5 g; Polysorbate 80, was purchased from Fluka 59924 - 100 g.
[00157] Lyophilization was done on the Leybold Lyovac GT2 equipment. LCMS (liquid chromatography with mass spectrometry) was run on an HP1100 system using acetonitrile - 0.1% trifluoroacetic acid and water as the eluent. An ACE C8 column, 50 x 3 mm and a 10-97% acetonitrile gradient in 3 min was used. The filtration bottles were from Whatman, Mino-UniPrep, 0.45 pm. (i) Method A, lyophilization
[00158] Melfalana flufenamide (30.1 mg) was dissolved in 5 ml of 70% ethanol with 1 mM HCI, total dissolution within 12 min at 18-19 ° C. The solution was diluted with water (70 ml) and distributed (10 ml) in 250 ml round bottom flasks with and without excipient (for example, β-cyclodextrin, 9 mg). When all the material had dissolved, the solutions were frozen by immersion in a dry ice / acetone bath at -78 ° C. The frozen solutions were then lyophilized at <0.1 mbar (10,000 mPa) for one night at room temperature, evaporation keeping the samples frozen until dry. (ii) Method A, measure of the dissolution rate
[00159] A 5% glucose solution (10 mL) was added in one portion at 18.5-19 ° C to the lyophilized material and stirred with a magnet. Aliquots (ca 0.3 mL) were tolerated with a 1 mL syringe at various times and filtered through a filtration vial (0.45 mm). The filtrate (8 ml) was analyzed by HPLC. (iii) Method B, lyophilization
[00160] Melfalana flufenamide (10.2 mg) was dissolved in 1.67 ml of 70% ethanol with 5 mM HCI, total dissolution within 5 min at 25 ° C. The solution was diluted with water (23.3 ml) and distributed (10 ml) in vials with and without excipients (for example, β-cyclodextrin, 9 mg). The J1 solution and the excipient were dispensed in plastic bottles with a 0.45 pm filter inserted and adjusted (0.25 mL for each bottle). The vials were frozen by immersion in a dry ice / acetone bath at -78 ° C and then kept at -20 ° C for one night in a support fitted to the vials. The frozen bottles were covered with aluminum foil to prevent cross contamination and keep the pre-frozen support at -20 ° C, while exposing the support in a desiccator at <0.1 mbar (10,000 mPa) for one night, evaporation keeping the samples frozen until dry. (iv) Method B, measure of the dissolution rate
[00161] A 5% glucose solution (0.5 mL) was added, which contained an internal standard (3-methoxybenzoic acid, 0.08 mg / mL). After several times (15 s - 12 min) the contents of the vials were filtered, the filtrate directly transferred to the glass vials to prevent leakage of undissolved material in the filtrate and 8 pL of the filtrate injected into the LCMS. Determination of the dissolution rate
[00162] In a first approach, Method A, aqueous solutions of J1 with different additives were lyophilized in round bottom flasks. For each lyophilized compound, a glucose solution was added with controlled stirring. Small aliquots were removed with a syringe at specific times and filtered through a 0.45 pm GHP syringe filter. The degree of dissolution of J1 in the filtrate was then determined by HPLC. This method was used with lyophilized fluphenamide melphalan alone and combined with D-mannitol, trehalose, sucrose, Polysorbate-80 and β-cyclodextrin. The results of these tests showed that J1 was supplemented dissolved within 2-4 min despite the excipient (see, Fig. 1, without excipients, and Fig. 2, with excipients. See also, Table 7). In fact, the dissolution rate for lyophilized J1 with excipients was actually faster than can be measured using this method. Table 7. Additions of excipients to J1 (4 mg) in the lyolizer, Method A.

[00163] To improve accuracy and allow measurement of dissolution at shorter intervals, Method B was developed. In this method, aqueous solutions of melphalan flufenamide and excipients (see Table 2) were added to 2 ml plastic flasks and lyophilized. Then a glucose solution with internal standard 3-methoxybenzoic acid was added without stirring. After varying times (15 s - 6 min) the contents of the flask were filtered with an insertion in the 0.45 pm GHP flask, the filtrate transferred to a glass flask and the degree of melphalan hydrochloride flufenamide (J1) determined by HPLC with internal standard. The absence of agitation made a slower dissolution process possible, both more clinically relevant and easier to measure the kinetics of. With this method, the lyophilized J1 dissolution kinetics can be followed to compete the dissolution after 3-4 min (see Fig. 3, without excipients and Fig. 4, with excipients, see also Ta-bela 8). Table 8. Addition of excipients to J1 (4 mg) in lyophilization, Method B.

[00164] The dissolution rate of J1, with and without additives, determined with Method A and Method B, are summarized in Table 9. Table 9. Summary of dissolution times of J1 with and without additives, Methods A and B.

J1 purity and recovery
[00165] The sample of melphalan hydrochloride flufenamide (J1) was dissolved in acetonitrile aq. 50% and analyzed immediately with LCMS (liquid chromatography-mass spectrometry), showing only one peak (> 99%). The purity of J1 directly after dissolving in 70% ethanol containing 1 mM HCI or 5 mM HCI was found to be ca 97%, with a minor by-product of ca 3%. The amount of this by-product is increased if the solution is left at room temperature.
[00166] The results demonstrate that the speed of dissolution of lyophilized J1 in glucose solution with stirring was faster than can be measured (Method A), not allowing the effect of excipient additions to be seen. Using a more clinically revealing Method B without agitation, the dissolution of lyophilized fluphenamide melphalan in glucose solution can be followed to complete after 3-4 minutes. Addition of excipients β-cyclodextrin, Polysorbate 80, Mannitol and Trealose to the melphalan flufenamide solution before lyophilization, in all, gave complete dissolution in less than 1 minute. The fastest dissolution was given by adding Polysorbate 80, giving complete dissolution in the first 15 second time point. Example 2: Test of the effect of concentration of the excipient Polysorbate 80 on the dissolution rate of melphalan flufenamide
[00167] The following was done to test the amount of excipient Polysorbate 80 to be added in the lyophilization process of melphalan flufenamide and to maximize the dissolution rate in a 5% glucose solution. 0, 10, 50 and 100% by weight, compared to the polysorbate 80 fluphenamide melphalan was used. The experiments were run in duplicate.
[00168] Flufenamide melphalan hydrochloride (J1) was used in all experiments. Polysorbate 80 was purchased from Fluka, 59924-100 g.
[00169] Lyophilization was performed on a Leybold Lyovac GT2 device. LCMS was run on an HP1100 system using acetonitrile-0.1% trifluoroacetic acid in water as the eluent. An ACE C8 column, 50 x 3 mm and a 10-97% acetonitrile gradient in 3 min was used. The glass bottles were from Whatman, Mini-UniPrep, 0.45 pm.
[00170] General preparation of 2 mg / mL of stocked melphalan stock solution before lyophilization was done as follows:
[00171] 11.0 mg of melphalan flufenamide was suspended in a solution of 10 mM HCI in absolute EtOH (0.5 ml). The mixture was stirred for 30 minutes before 0.2 ml of water was added. The mixture was stirred for 10 minutes at room temperature (clear solution) before being added to a 0 ° C water solution (4.8 ml). 0.25 ml of the solution was transferred to a plastic container containing 10%, 50% or 100% by weight of Polysorbate 80. The flask was shaken, cooled and lyophilized.
[00172] A 5% glucose solution with an internal standard 3-methoxybenzoic acid was prepared by dissolving 3-methoxybenzoic acid (1.2 mg) in water (15 ml). The mixture was stirred for 1 hour before 750 mg of glucose was added while stirring. 0.5 ml of the 5% glucose solution was added to each lyophilized plastic container and the mixtures were filtered, at different time points, transferred to a glass container and the dissolution of J1 was determined by HPLC. Determination of the dissolution rate
[00173] J1 (11 mg) was suspended in EtOH (0.5 ml) and stirred for 30 minutes at room temperature before water (5 ml) was added. The solution was divided into 4 different flasks containing 0%, 10%, 50% or 100% weight (in relation to J1) of Polysorbate 80. The solutions were transferred to 2 ml plastic containers and lyophilized for one night.
[00174] A 5% glucose solution with an internal standard 3-methoxybenzoic acid was added to each container without stirring and the mixtures were filtered through insertion into the 0.45 pm GHP container at different time points (2-300 seconds ). The filtrate was immediately transferred to a glass container to prevent leakage of undissolved material. The amount of dissolved J1 relative to the internal standard was determined using HPLC. Results
[00175] The rate of dissolution of J1 (1 mg / mL in 5% glucose solution) with and without Polysorbate 80, is summarized in Table 10 and revealed in Fig. 5. Table 10.

[00176] Table 10 shows that all samples containing lyophilized J1 and the excipient Polysorbate 80 dissolve much faster than lyophilized J1 in the absence of the excipient. Special attention was given to the sample containing 10% Polysorbate 80 and the timing points in this experiment were: immediate filtration, 2 seconds, 15 seconds, 30 seconds and 5 minutes. The first time point where the sample was immediately filtered, approximately 40% was dissolved and after 2 seconds approximately 70% was dissolved. Complete dissolution was achieved after 30-60 seconds. The dissolution rate of lyophilized J1 at 1 mg / mL containing varying amounts of Polysorbate 80 in a 5% glucose solution was below 1 minute for all samples. The lowest amount of Polysorbate 80 for rapid dissolution was between 10 and 50% by weight. Example 4: Test of the effect of concentrations of the excipients Polysorbate 80, PEG400 and β-cyclodextrin on the dissolution rate of melphalan flufenamide
[00177] This example was done to study the effect of different concentrations of the excipients Polysorbate 80, PEG400 and β-cyclodextrin added in the lyophilization process of melphenan flufenamica to maximize the solubility and speed of dissolution in a 5% glucose solution for the long-term goal of developing a lyophilized material, stable for storage and easy to prepare for dosing.
[00178] Flufenamide melphalan hydrochloride (J1) was used in all experiments. Polysorbate 80 used was purchased from Fluka (59924-100 g), β-cyclodextrin from Aldrich (856088) and PEG400 from Clariant (100316).
[00179] Lyophilization was performed on a Leybold Lyovac GT2 device. LCMS was run on an HP1100 system using acetonitrile-0.1% trifluoroacetic acid and water as the eluent. An ACE C8 column, 50 x 3 mm and a 10-97% acetonitrile gradient in 3 min was used. The filtration vessels were from Whatman, Mino-UniPrep, 0.45 pm. General preparation of 2 mg / mL of flufenamide melphalan stock solution for lyophilization 11.1 mg of flufenamide melphalan was suspended in a 10 mM HCI solution in abstracted EtOH (0.5 ml). The mixture was stirred for 30 minutes before 0.2 ml of water was added. The mixture was stirred for 10 minutes at room temperature (clear solution) before being added dropwise to a 0 ° C solution of water (4.8 ml). 0.25 mL or 0.5 mL of the solution was transferred to a plastic container containing the excipients. The vessel was shaken, cooled and lyophilized. Solubility experiment
[00180] A 5% glucose solution with an internal standard was prepared by dissolving 3-methoxybenzoic acid (1.2 mg) in water (15 ml). The mixture was stirred for 1 hour before 750 mg of glucose was added while stirring. 0.2 mL of 5% glucose solution was added to each lyophilized plastic container and the mixtures were stirred for 10-15 seconds and filtered after 5 minutes. The filtrate was transferred to a glass vessel and the solubility of melphalan flufenamide was determined by HPLC and a calibration curve. Determination of solubility
[00181] A 2 mg / mL stock solution of flufenami-melphalan hydrochloride (J1) was used as in the previous experiments.
[00182] For a solubility of 2.5 mg / mL of J1 in 5% glucose solution, 0.25 mL of the stock solution was dispensed in 2 mL plastic containers containing a mixture of excipients determined by experimental design and the mixtures were immediately cooled and lyophilized.
[00183] The high / low levels of each excipient (by weight-% relative to melfa-lana flufenamide) were as follows: Polysorbate 80 (8% -80%), PEG400 (80% - 400%) and β-cyclodextrin ( 10% -50%). The highest amount of each excipient was determined from the FDA's Inactive Ingredient database of registered IV-administered drugs, β-cyclodextrin is on the FDA's GRAS list (Generally Recognized as Safe) but no recommendation is given for injections. trapped by our knowledge, which caused a reasonably high level of conservation to be adjusted. The weight percentage of each excipient in relation to the fluphenamide melphalan hydrochloride (J1) (weight) is shown in Table 11. Table 11. Weight percentage of each excipient in relation to J1.


[00184] As demonstrated here in other experiments here, the dissolution rate of J1 increased greatly with the addition of Polysorbate 80 in the lyophilization process. Three experiments were done to try to achieve a solubility of 5 mg / mL. A stock solution of J1 was added to 3 different plastic containers (exp 12, 13 and 14) containing Polysorbate 80 (10%, 50% and 100% by weight in relation to melphalan flufenamide). The mixtures were immediately cooled and lyophilized.
[00185] A 5% glucose solution with an internal standard (3-methoxybenzoic acid) was added to each container and the containers were shaken and allowed to rest for 5 minutes. The mixtures were filtered through a 0.45 pm GHP filter container and the filtrate was immediately transferred to a glass container to prevent leakage of undissolved material. The amount of dissolved J1 was determined using HPLC and a calibration curve. Results
[00186] The solubilities of J1 in mg / mL with high / low levels of the excipients Polysorbate 80, PEG400 and β-cyclodextrin are summarized in Table 12. Table 12. Solubility of J1 in mg / mL.

★ Experiments 15-16 do not use lyophilized J1, fine powder was used in Experiment 15 and large masses were used in Experiment 16.
[00187] The results provided in Table 12 demonstrate that the solubility of J1 increased in all experiments containing excipients compared to non-lyophilized J1 (between 15 and 16). The large discrepancy in the solubility of non-lyophilized J1 is probably due to the difference in particle size in the batch, since entry 15 was a suspension of fine powders, while entry 16 were larger masses giving lower dissolution rate and therefore solubility J1 in 5 minutes. The analysis precision is shown in the central experiments 9-11 (1.9, 1.8 and 1.7) with identical concentrations of excipients. The 3 samples with Polysorbate 80 as the excipient (10, 50 and 100%) exhibited a solubility of 1.0, 1.2 and 1.4 g / mL, respectively.
[00188] Entries with the mixture of excipients Polysorbate 80, PEG400 and β-cyclodextrin exhibited various combinations with solubilities at or close to 2.0 mg / mL. The higher solubilities determined 2.0 (entries 3, 5 and 7) were only possible with high levels of PEG400, giving liquids or semi-solids after lyophilization.
[00189] Samples with a lower amount of PEG400 (entries 2, 4, 6 and 8) formed a powdery white powder after lyophilization, with the highest determined solubility of 1.9 mg / mL at entry 8. Then it was quickly tested whether greater solubility can be obtained by decreasing the amount of PEG400 and increasing the amount of β-cyclodextrin. An additional sample (line 17 in Table 12) was lyophilized containing 50% Polysorbate 80, 80% PEG400 and 100% β-cyclodextrin. The solubility of J1 with this mixture of excipients was 1.2 mg / ml.
[00190] The results demonstrate that the maximum solubility of J1 with excipient combinations is close to 2 mg / mL.
[00191] With experiment 13 it was shown that a solution of J1 with 50% Polysorbate gave a solubility of approximately 1.2 mg / mL alone, sufficient for a 1.0 mg / mL formulation and allowing the exclusion of PEG400 and β- cyclodextrin. Visual confirmation experiments
[00192] To confirm the dissolution in a more clinically relevant form, an experiment on a larger scale in transparent glass containers instead of plastic containers was performed. Container 1 contained a 4.8 mg solution of melfapan flufenamide hydrochloride (J1) and 2.4 mg of Polysorbate 80. As a control container 2 it contained 4.8 mg of melphalan flufenamide hydrochloride (J1) and no Polysorbate 80. The containers were freeze-dried for one night.
[00193] To each container containing the lyophilized J1 melphalan as a white powdery material, 4.70 mL of a 5% glucose solution was added to give a J1 concentration of 1.02 mg / mL. The mixtures were stirred for 10-15 seconds and the test tube containing J1 and 50% Polysorbate 80 showed a clear solution after 15 seconds, see Fig. 6, container on the left. The reference tube with lyophilized J1 without Polysorbate showed small particles and was not completely dissolved after 30 minutes, see Fig. 6, container on the right. LC-MS analysis revealed that the purity of melphalan flufenamide after 30 minutes was> 95%, in both containers.
[00194] The results provided here demonstrate that the solubility of J1 in 5% glucose solution can be increased using a mixture of excipients Po-lysorbate 80, PEG400 and β-cyclodextrin at 1.9 mg / ml. Such a mixture of excipients with J1 resulted in a powdery white solid on lyophilization.
[00195] Lyophilization of J1 with 50% - Polysorbate 80 weight, resulted in a fluffy white solid that is quickly dissolved in 5% glucose solution. The 1.2 mg / mL saturation concentration is sufficient for use in a clinical setting for 1.0 mg / mL dose preparation. Example 5: Stability test
[00196] The purpose of the first part of this study was to investigate the dissolution rate of the fluphenamide melphalan hydrochloride (J1) (lyophilized together with Polisor-bato 80) in a 5% glucose solution.
[00197] The rate of dissolution of J1 (lyophilized) in a 5% glucose solution containing Polysorbate 80 will be measured in another experiment.
[00198] Finally, the dissolution rate of un Lyophilized J1 in a 5% glucose solution containing Polysorbate 80 will be measured.
[00199] The second part is an investigation of the degradation of J1 in two different preparations at elevated temperature. The first preparation was a lyophilized solid containing polysorbate 80 and the second was a solution of 25 mg / ml J1 in N, N-dimethylacetamide (DMA). Degradation was followed for 1 month at + 40 ° C, using two preparations (i) Determination of the dissolution rate
[00200] A 5% glucose solution was added to each plastic container containing J1. The recipients were shaken and filtered at different times. The filtrate was transferred to glass containers and the amount of J1 dissolved was determined by HPLC. (ii) Design of the accelerated stability study
[00201] 10 containers with lyophilized J1 and Polysorbate 80, and 10 containers of J1 solution in DMA, were stored at 40 ° C for 1 month. Two containers of the lyophilized material (called lyophilisate 1 and 2 in the table below) and one container of the DMA solution (called DMA in table 1 below) were removed from the 40 ° C chamber and stored at -20 ° C and analyzed at the same time. test time and J1 purity. Sample times were 0, 1, 3, 10 and 30 days. Each lyophilized container contained 25 mg J1 solution. The 25 mg / mL solution in DMA was from On-copeptides. (iii) Analysis and Results
[00202] The lyophilized samples were dissolved in 500 pL of DMA in Whatman 0.45 pm filter containers. The samples were stirred briefly before pressing the two parts of the container together and then filtering the sample. Samples of 25 mg / mL solution were diluted with DMA by aliquoting 20 µL of solution into HPLC containers and diluting with 980 µL of DMA. 4 pL were injected into the chromatographic system.
[00203] The stability was evaluated as the relative purity, since there was a slight variation in the amount of J1 in the lyophilized containers. By using relative purity, each sample is standardized against itself and the effect of J1 quantity variation is minimized on the stability result. The rate of dissolution of J1 in glucose 5% in the presence of PS is summarized in table 13: Table 13: Summary of the dissolution experiments.
Results of the stability test Table 14. Results of the stability test at 40 ° C, comparison between DMA solution and lyophilized J1 at + 40 ° C / Relative Humidity of the Environment

[00204] The results in table 14 show that the lyophilized material is essentially unloaded during the test period. Only a small change in purity can be observed. Also the dissolution rate of lyophilized J1 at 1 mg / mL in a 5% glucose solution was below 1 min in the presence of Polysorbate 80. The dissolution rate of 1 mg / mL non-lyophilized J1 in a glucose solution 5 % containing Polysorbate 80 was estimated for 1-2 min.
[00205] J1 in the DMA solution degraded significantly during storage at + 40 ° C for one month. The relative quantity decreased from about 96.8% to 86.9%. J1 stored as a lyophilized solid only showed a small degradation from 98.7% to 98.3% during the same period of time. Other modalities
[00206] It is to be understood that while the invention has been described in conjunction with its detailed description, the above description is intended to illustrate and not to limit the purpose of the invention, which is defined by the purpose of the appended claims . Other advantageous aspects and modifications are within the scope of the following claims.

权利要求:
Claims (16)
[0001]
1. Freeze-dried pharmaceutical preparation CHARACTERIZED by the fact that it comprises: (i) melphalan hydrochloride flufenamide (J1); and (ii) sucrose.
[0002]
2. Freeze-dried pharmaceutical preparation according to claim 1, CHARACTERIZED by the fact that the amount of sucrose is about 10 to 100% by weight of said fluphenamide melphalan hydrochloride (J1).
[0003]
3. Freeze-dried pharmaceutical preparation, according to claim 2, CHARACTERIZED by the fact that the amount of excipient is 10 to 50% by weight of said fluphenamide melphalan hydrochloride (J1).
[0004]
4. Lyophilized pharmaceutical preparation according to any one of claims 1 to 3, CHARACTERIZED by the fact that it further comprises a physiologically acceptable solution.
[0005]
5. Freeze-dried pharmaceutical preparation according to claim 4, CHARACTERIZED by the fact that said physiologically acceptable solution is a glucose solution.
[0006]
6. Freeze-dried pharmaceutical preparation according to claim 5, CHARACTERIZED by the fact that the amount of glucose is 4.5 to 5.5% by weight of the freeze-dried preparation.
[0007]
7. Freeze-dried pharmaceutical preparation according to any one of claims 1 to 6, CHARACTERIZED by the fact that it comprises 25 mg of melphalan hydrochloride flufenamide (J1) and 12.5 mg of sucrose.
[0008]
8. Freeze-dried pharmaceutical preparation according to any one of claims 1 to 7, CHARACTERIZED by the fact that it is free or substantially free of organic solvents.
[0009]
9. Freeze-dried pharmaceutical preparation, according to any of claims 1 to 8, CHARACTERIZED by the fact that it is for use as a medication.
[0010]
10. Freeze-dried pharmaceutical preparation according to any one of claims 1 to 8, CHARACTERIZED by the fact that it is for use in the treatment and / or prevention of cancer.
[0011]
11. Method for preparing a lyophilized pharmaceutical preparation, as defined in any one of claims 1 to 8, CHARACTERIZED by the fact that: a. flufenamide melphalan hydrochloride (J1) is dissolved in an organic solvent to obtain a solution of flufenamide melphalan hydrochloride (J1); B. water is added to the fluphenamide melphalan hydrochloride solution (J1) in order to obtain an aqueous solution of melphalan flufenamide hydrochloride (J1), in a concentration of about 0.2 to 3.0 mg / mL; ç. sucrose is added to the fluphenamide melphalan hydrochloride solution (Jl), and d. the aqueous solution of melphalan flufenamide hydrochloride (J1) containing sucrose is subjected to lyophilization.
[0012]
12. Method, according to claim 11, CHARACTERIZED by the fact that: a. flufenamide melphalan hydrochloride (J1) is dissolved in an organic solvent; B. water is added to the solution obtained in step a) in order to obtain a solution of said fluphenamide melphalan hydrochloride (J1) in a concentration of about 0.2 to 3.0 mg / mL; ç. Sucrose is added to the solution obtained in step b); and d. the solution obtained in step c) is subjected to lyophilization.
[0013]
13. Method according to claim 11 or 12, CHARACTERIZED by the fact that the organic solvent is selected from any one of ethanol, ethanol containing acid, glycerin, propylene glycol, benzyl alcohol, dimethylacetamide (DMA), N-methyl-2-pyrrolidone, isopropanol, n-butanol, tert-butanol, methyl tert-butyl ether, dimethyl sulfoxide, tetrahydrofuran, 2-methyl tetrahydrofuran, acetone, dimethylformamide, acetonitrile, dioxane, acetic acid, lactic acid, acid propionic, n-propanol, sec-butanol, methanol and a mixture of ethanol and water.
[0014]
14. Method according to claim 11 or 12, CHARACTERIZED by the fact that the organic solvent is ethanol.
[0015]
15. Use of sucrose CHARACTERIZED by the fact that it is in a lyophilized preparation of melphalan flufenamide hydrochloride (J1) to decrease the reconstitution time of the lyophilized preparation of melphalan flufenamide hydrochloride (J1), when reconstituted in an aqueous solvent.
[0016]
16. Use, according to claim 15, CHARACTERIZED by the fact that said flufenamide melphalan hydrochloride (J1) is dissolved in ethanol before subjecting said flufenamide melphalan hydrochloride (J1) to said excipient.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112013027584B1|2020-11-03|lyophilized pharmaceutical preparation of cytotoxic dipeptides, method for preparing the same and use of sucrose in said preparation

---

CA2889753C|2021-03-02|Lyophilized preparations of melphalan flufenamide

---

IL280812D0|2021-04-29|Lyophilized preparation of cytotoxic dipeptides

---

BR122019017088B1|2021-11-16|LYophilized PHARMACEUTICAL PREPARATION OF CYTOTOXIC DIPEPTIDES, KIT CONTAINING SUCH PREPARATION, USE OF THE SAME TO TREAT AND/OR PREVENT CANCER, METHOD FOR PREPARING SUCH PREPARATION AND USE OF AN EXCIPIENT IN SUCH PREPARATION

---

ES2768268T3|2020-06-22|Lyophilized preparations of melphalan flufenamide

---

NZ617197B2|2015-09-29|Lyophilized preparation of cytotoxic dipeptides

同族专利:

---

公开号 | 公开日

---

EP3228319B1|2020-06-03|

---

KR20140041497A|2014-04-04|

---

US20190240332A1|2019-08-08|

---

NZ617197A|2015-06-26|

---

ES2642676T3|2017-11-17|

---

KR20170140409A|2017-12-20|

---

MX345102B|2017-01-16|

---

AU2012247545B2|2016-08-11|

---

IL265457D0|2019-05-30|

---

PL3228319T3|2021-02-08|

---

ZA201308765B|2016-02-24|

---

CY1119453T1|2018-03-07|

---

IL265457A|2021-02-28|

---

BR112013027584A2|2016-09-06|

---

EP3656393A1|2020-05-27|

---

JP6042412B2|2016-12-14|

---

CA3024230A1|2012-11-01|

---

US10543274B2|2020-01-28|

---

LT2701720T|2017-11-10|

---

CA2833500C|2019-01-08|

---

KR101808895B1|2017-12-13|

---

MX2013012545A|2014-04-16|

---

HUE037863T2|2018-09-28|

---

SI3228319T1|2020-10-30|

---

RS60719B1|2020-09-30|

---

US20170049894A1|2017-02-23|

---

RS56462B1|2018-01-31|

---

CN103547279A|2014-01-29|

---

US20200345848A1|2020-11-05|

---

PL2701720T3|2017-12-29|

---

AU2012247545A1|2013-10-31|

---

US20140128462A1|2014-05-08|

---

CA2833500A1|2012-11-01|

---

US10322182B2|2019-06-18|

---

CN108096563A|2018-06-01|

---

IL228889D0|2013-12-31|

---

PT2701720T|2017-10-20|

---

EP2701720B1|2017-07-12|

---

KR102122416B1|2020-06-12|

---

US20200121794A1|2020-04-23|

---

RU2597154C2|2016-09-10|

---

US20200009252A1|2020-01-09|

---

WO2012146625A1|2012-11-01|

---

SI2701720T1|2017-11-30|

---

EP3228319A1|2017-10-11|

---

JP2014512402A|2014-05-22|

---

US10869928B2|2020-12-22|

---

DK2701720T3|2017-10-09|

---

DK3228319T3|2020-09-07|

---

EP2701720A1|2014-03-05|

---

HRP20171523T1|2017-11-17|

---

RU2013152751A|2015-06-10|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB750155A|1953-03-17|1956-06-13|Nat Res Dev|Substituted alanines|

---

GB8727157D0|1987-11-19|1987-12-23|Wellcome Found|Pharmaceutical formulations|

---

US5595756A|1993-12-22|1997-01-21|Inex Pharmaceuticals Corporation|Liposomal compositions for enhanced retention of bioactive agents|

---

DE60141398D1|2000-06-13|2010-04-08|Oncopeptides Ab|MELPHALAN DERIVATIVES AND THEIR USE AS CHEMOTHERAPEUTICS AGAINST CANCER|

---

SE0002202D0|2000-06-13|2000-06-13|Karolinska Innovations Ab|New peptides|

---

PT1478339E|2002-02-22|2008-09-05|Schering Corp|Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same|

---

US6780324B2|2002-03-18|2004-08-24|Labopharm, Inc.|Preparation of sterile stabilized nanodispersions|

---

US7323479B2|2002-05-17|2008-01-29|Celgene Corporation|Methods for treatment and management of brain cancer using 1-oxo-2--4-methylisoindoline|

---

US20040034099A1|2002-06-27|2004-02-19|Ramsey Beverly J.|Pharmaceutical composition|

---

US20050152979A1|2003-09-05|2005-07-14|Cell Therapeutics, Inc.|Hydrophobic drug compositions containing reconstitution enhancer|

---

KR101188691B1|2004-10-29|2012-10-09|파르마 마르 에스.에이.|Formulations comprising ecteinascidin and a disaccharide|

---

EP1674098A1|2004-12-23|2006-06-28|Schering Aktiengesellschaft|Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water|

---

GB0522082D0|2005-10-31|2005-12-07|Pharma Mar Sa|Formulations|

---

MX2009000235A|2006-07-07|2009-01-23|Gilead Sciences Inc|Novel pyridazine compound and use thereof.|

---

CN101584669B|2009-06-19|2010-12-29|江苏奥赛康药业有限公司|Melphalan freeze-dried powder injection|

---

WO2011078782A1|2009-12-22|2011-06-30|Oncopeptides Ab|A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer|

---

AR077384A1|2010-07-05|2011-08-24|Eriochem Sa|AN INJECTABLE PHARMACEUTICAL FORMULATION OF MELFALANO.|

---

PT2696848T|2011-04-15|2020-09-03|Janssen Pharmaceutica Nv|Freeze dried drug nanosuspensions|

---

PL3228319T3|2011-04-28|2021-02-08|Oncopeptides Ab|Lyophilized preparation of cytotoxic dipeptides|

---

RS60068B1|2012-10-26|2020-05-29|Oncopeptides Ab|Lyophilized preparations of melphalan flufenamide|PL3228319T3|2011-04-28|2021-02-08|Oncopeptides Ab|Lyophilized preparation of cytotoxic dipeptides|

---

JP5827178B2|2012-06-05|2015-12-02|北越紀州製紙株式会社|Cellulose porous body and method for producing the same|

---

RS60068B1|2012-10-26|2020-05-29|Oncopeptides Ab|Lyophilized preparations of melphalan flufenamide|

---

ES2768268T3|2012-10-26|2020-06-22|Oncopeptides Ab|Lyophilized preparations of melphalan flufenamide|

---

GB201507903D0|2015-05-08|2015-06-24|Oncopeptides Ab|Process for preparation of nitrogen mustard derivatives|

---

GB201521217D0|2015-12-01|2016-01-13|Oncopeptides Ab|Dosage regimens|

---

US10369077B2|2017-05-31|2019-08-06|Adienne Pharma & Biotech Sa|Multi chamber flexible bag and methods of using the same|

---

SG11202103726RA|2018-10-18|2021-05-28|Oncopeptides Ab|Compounds containing deuterium|

---

WO2020201542A1|2019-04-03|2020-10-08|Oncopeptides Ab|Treatment of al amyloidosis with melflufen|

---

GB201905477D0|2019-04-17|2019-05-29|Oncopeptides Ab|Novel formulations|

---

WO2021053185A1|2019-09-20|2021-03-25|Oncopeptides Ab|Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma|

---

GB202109894D0|2021-07-08|2021-08-25|Oncopeptides Ab|Novel treatments|

---

GB202109896D0|2021-07-08|2021-08-25|Oncopeptides Ab|Novel treatments|

---

GB202109895D0|2021-07-08|2021-08-25|Oncopeptides Ab|Novel treatments|

法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law|

---

2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|

---

2018-10-02| B25G| Requested change of headquarter approved|Owner name: ONCOPEPTIDES AB (SE) |

---

2019-03-19| B07E| Notice of approval relating to section 229 industrial property law|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-06-18| B06T| Formal requirements before examination|

---

2020-06-16| B09A| Decision: intention to grant|

---

2020-11-03| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/04/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

SE1150371|2011-04-28|

---

SE1150371-1|2011-04-28|

---

US201161535126P| true| 2011-09-15|2011-09-15|

---

US61/535,126|2011-09-15|

---

PCT/EP2012/057577|WO2012146625A1|2011-04-28|2012-04-25|Lyophilized preparation of cytotoxic dipeptides|

---